Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript May 12, 2025
Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.58 EPS, expectations were $-0.31.
Operator: Good afternoon. Welcome to the Relmada Therapeutics First Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded, and will be available for replay on the location website. I would like to turn the call over to Brian Ritchie from LifeSci...
